Gainers
- Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.
- Prothena Corp (NASDAQ:PRTA) stock moved upwards by 60.13% to $49.53. The company's market cap stands at $2.3 billion.
- SILO Pharma (NASDAQ:SILO) stock moved upwards by 54.31% to $7.87. The company's market cap stands at $15.6 million.
- Biogen (NASDAQ:BIIB) stock moved upwards by 47.72% to $292.19. The market value of their outstanding shares is at $42.4 billion.
- BioRestorative Therapies (NASDAQ:BRTX) stock rose 25.6% to $3.09. The market value of their outstanding shares is at $11.2 million.
- Longeveron (NASDAQ:LGVN) stock rose 24.31% to $5.01. The company's market cap stands at $105.1 million.
Losers
- PhaseBio Pharmaceuticals (NASDAQ:PHAS) stock declined by 34.2% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $24.9 million.
- Avenue Therapeutics (NASDAQ:ATXI) stock fell 13.23% to $6.3. The company's market cap stands at $9.2 million.
- eFFECTOR Therapeutics (NASDAQ:EFTR) stock declined by 10.91% to $0.5. The company's market cap stands at $20.8 million.
- Kiromic BioPharma (NASDAQ:KRBP) stock declined by 10.09% to $0.3. The company's market cap stands at $4.7 million.
- Aquestive Therapeutics (NASDAQ:AQST) shares fell 8.78% to $1.04. The market value of their outstanding shares is at $55.4 million.
- Aridis Pharmaceuticals (NASDAQ:ARDS) stock decreased by 8.77% to $0.67. The company's market cap stands at $11.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
AQSTAquestive Therapeutics Inc
$5.715.84%
ARDSAridis Pharmaceuticals Inc
$0.00020-99.9%
ATXIAvenue Therapeutics Inc
$0.9590-%
BIIBBiogen Inc
$167.02-0.32%
BRTXBioRestorative Therapies Inc
$1.340.75%
EFTReFFECTOR Therapeutics Inc
$0.00060-99.7%
LGVNLongeveron Inc
$0.6707-1.61%
PRTAProthena Corp PLC
$9.611.36%
SILOSILO Pharma Inc
$0.44016.51%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
